Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?

ISSN： 1340-6868

Source： Breast Cancer, Vol.18, Iss.2, 2011-04, pp. : 85-91

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Selection of Primary Breast Cancer Patients for Adjuvant Endocrine Therapy – is Oestrogen Receptor Alone Adequate?

By Cheung K.L.

Breast Cancer Research and Treatment, Vol. 65, Iss. 2, 2001-01 ,pp. : 155-162

Springer Publishing Company

Access to resources Recommend Favorite

Which is better in neoadjuvant treatment of breast cancer? Taxane followed by anthracyline or vice versa

By Altundag Kadri Altundag Ozden Baptista Mauricio Atik Mustafa

Breast Cancer Research and Treatment, Vol. 97, Iss. 2, 2006-05 ,pp. : 221-221

Springer Publishing Company

Access to resources Recommend Favorite

Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/ neu in Patients with Breast Cancer

By Taucher Susanne

Breast Cancer Research and Treatment, Vol. 82, Iss. 3, 2003-01 ,pp. : 207-213

Springer Publishing Company

Access to resources Recommend Favorite

Neoadjuvant endocrine therapy of breast cancer: a surgical perspective

By Dixon J.M. Anderson T.J. Miller W.R.

European Journal of Cancer, Vol. 38, Iss. 17, 2002-11 ,pp. : 2214-2221

Elsevier

Access to resources Recommend Favorite

Does the sequence of taxane administration affect the outcome of patients with breast cancer in the adjuvant and neoadjuvant settings?

By Alkan Ali

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1430-1430

Humana Press, Inc

Access to resources Recommend Favorite